US 11,891,425 B2
Thioamide-modified peptides and uses thereof
E. James Petersson, Wynnewood, PA (US); and Alan Saghatelian, Somerville, MA (US)
Assigned to THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US); and PRESIDENT AND FELLOWS OF HARVARD COLLEGE, Cambridge, MA (US)
Filed by THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US); and PRESIDENT AND FELLOWS OF HARVARD COLLEGE, Cambridge, MA (US)
Filed on Feb. 12, 2021, as Appl. No. 17/174,876.
Application 17/174,876 is a continuation of application No. 16/209,128, filed on Dec. 4, 2018, granted, now 10,947,290.
Application 16/209,128 is a continuation of application No. 15/305,681, granted, now 10,189,884, issued on Jan. 29, 2019, previously published as PCT/US2015/028008, filed on Apr. 28, 2015.
Claims priority of provisional application 61/985,045, filed on Apr. 28, 2014.
Prior Publication US 2021/0198338 A1, Jul. 1, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/605 (2006.01); A61K 9/00 (2006.01); A61K 38/26 (2006.01); C07K 1/113 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/605 (2013.01) [A61K 9/0019 (2013.01); A61K 38/26 (2013.01); C07K 1/1136 (2013.01); A61K 38/00 (2013.01)] 6 Claims
 
1. A method of treating diabetes or obesity in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a thioamide-modified peptide comprising the amino acid sequence of SEQ ID NO:2.